|Articles|October 1, 2012

ACT 2013 Rates

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

© photon_photo - © photon_photo - stock.adobe.com

Evolving Trial Designs Advance Precision Medicine Through Basket, Umbrella, and Platform Models

ByAndy Studna, Senior Editor

November 10th 2025

Bezuclastinib Plus Sunitinib Achieves Strong PFS Benefit in Phase III PEAK Trial for Imatinib-Resistant GIST

ByAndy Studna, Senior Editor

November 10th 2025

ACT Brief: AI, Caplyta Approval, and FDA Priority Vouchers

ByAndy Studna, Senior Editor

November 10th 2025

Scaling Recruitment Across Therapeutic Areas and Regions

ByMatt Holms,Andy Studna, Senior Editor

November 10th 2025

© putilov_denis - © putilov_denis - stock.adobe.com

FDA Approves Caplyta as Adjunctive Therapy for Major Depressive Disorder Based on Positive Phase III Results

ByAndy Studna, Senior Editor

November 7th 2025

ACT 2013 Rates

Newsletter

Related Content

Evolving Trial Designs Advance Precision Medicine Through Basket, Umbrella, and Platform Models

Bezuclastinib Plus Sunitinib Achieves Strong PFS Benefit in Phase III PEAK Trial for Imatinib-Resistant GIST

ACT Brief: AI, Caplyta Approval, and FDA Priority Vouchers

Scaling Recruitment Across Therapeutic Areas and Regions

FDA Approves Caplyta as Adjunctive Therapy for Major Depressive Disorder Based on Positive Phase III Results

Trending on Applied Clinical Trials Online

Evolving Trial Designs Advance Precision Medicine Through Basket, Umbrella, and Platform Models

Scaling Recruitment Across Therapeutic Areas and Regions

Bezuclastinib Plus Sunitinib Achieves Strong PFS Benefit in Phase III PEAK Trial for Imatinib-Resistant GIST

ACT Brief: AI, Caplyta Approval, and FDA Priority Vouchers